Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 5:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 105 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ixempra (Ixabepilone (BMS-247550) ) Clear all
Terminated Phase 2 Interventional Results available

Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer

NCT00546364
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2, Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2, Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
60
States / cities
Tuscaloosa, Alabama • La Jolla, California • Southington, Connecticut + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons

NCT00627978
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
ixabepilone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 10, 2026, 5:20 PM EDT
Terminated Phase 2 Interventional Results available

Ixabepilone to Treat Cervical Cancer

NCT00924066
View directory record Official record
Conditions
Cervical Carcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Carcinoma, Non-SquamousType
Interventions
Ixempra (Ixabepilone (BMS-247550) )
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 1 Interventional

Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies

NCT00207129
View directory record Official record
Conditions
Advanced Solid Tumors, Neoplasms
Interventions
Ixabepilone, Capecitabine
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 1 Interventional

Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer

NCT01084057
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
vorinostat, ixabepilone, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 3 Interventional Results available

Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

NCT00080301
View directory record Official record
Conditions
Breast Cancer, Metastases
Interventions
Ixabepilone + Capecitabine, Capecitabine
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older · Female only
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
32
States / cities
Little Rock, Arkansas • San Francisco, California • Vallejo, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 1Phase 2 Interventional

Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer

NCT00025194
View directory record Official record
Conditions
Prostate Cancer
Interventions
estramustine phosphate sodium, ixabepilone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 1 Interventional

Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors

NCT00884676
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Ixabepilone, Sunitinib
Drug
Lead sponsor
Jaime Merchan
Other
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 2 Interventional Results available

Ixabepilone in Treating Patients With Metastatic Prostate Cancer

NCT00087139
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
ixabepilone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
162
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 114 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 1 Interventional Results available

A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer

NCT00422097
View directory record Official record
Conditions
Cancer
Interventions
Ixabepilone, 5 mg/d, Ixabepilone, 10 mg/d, Ixabepilone, 15 mg/d, Ixabepilone, 20 mg/d, Ixabepilone, 25 mg/d, Ixabepilone, 30 mg/d, Ixabepilone, 25 mg, with famotidine, Ixabepilone, 25 mg, with food
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 2 Interventional

BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy

NCT00017043
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
ixabepilone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 2 Interventional

BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00016393
View directory record Official record
Conditions
Prostate Cancer
Interventions
ixabepilone
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
28
States / cities
Los Angeles, California • Sacramento, California • Atlanta, Georgia + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 10, 2026, 5:20 PM EDT
Terminated Phase 1 Interventional

BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors

NCT00028561
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ixabepilone, carboplatin, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 10, 2026, 5:20 PM EDT
Terminated No phase listed Observational

Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

NCT03393741
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Taxane, Vinorelbine, Ixabepilone, Eribulin, Chemotherapy
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 1 Interventional

S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction

NCT00049400
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
BMS-247550
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
23
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 10, 2026, 5:20 PM EDT
Withdrawn Phase 1 Interventional

Ixabepilone and Pemetrexed/Solid Tumors

NCT01170871
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Ixabepilone, Pemetrexed
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 10, 2026, 5:20 PM EDT
Terminated Phase 2 Interventional

Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

NCT01057212
View directory record Official record
Conditions
Non-squamous Non-small Cell Lung Cancer
Interventions
ixabepilone, bevacizumab
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 7, 2015 · Synced Oct 10, 2026, 5:20 PM EDT
Withdrawn Phase 2 Interventional

Ixabepilone and SBRT For Metastatic Breast Cancer

NCT01818999
View directory record Official record
Conditions
METASTATIC BREAST CANCER
Interventions
IXABEPILONE, STEREOTACTIC BODY RADIATION THERAPY
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 2 Interventional Results available

Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer

NCT01168232
View directory record Official record
Conditions
Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma
Interventions
Ixabepilone, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
78
States / cities
Little Rock, Arkansas • Concord, California • Walnut Creek, California + 54 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 1 Interventional

A Study of the Alternative Administration of Ixabepilone and Vinflunine

NCT00362830
View directory record Official record
Conditions
Cancer
Interventions
vinflunine + ixabepilone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Miami, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Oct 10, 2026, 5:20 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

NCT00977574
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Stage IIIA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IIIB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IIIC Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
Interventions
Bevacizumab, Carboplatin, Ixabepilone, Laboratory Biomarker Analysis, Paclitaxel, Temsirolimus
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
230
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 163 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 1 Interventional

BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

NCT00004927
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ixabepilone
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
2
States / cities
Detroit, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 2 Interventional

Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast Cancer

NCT00045097
View directory record Official record
Conditions
Breast Cancer
Interventions
ixabepilone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
4
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer

NCT00455533
View directory record Official record
Conditions
Breast Cancer
Interventions
Ixabepilone, Paclitaxel, Cyclophosphamide, Doxorubicin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Palm Springs, California • Coral Spring, Florida • Davie, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 10, 2026, 5:20 PM EDT